US Edition
Published • loading... • Updated
Subcutaneous Tepezza Matches Infusion in Phase 3 Trial, Amgen Reports
Summary by Patient Worthy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Subcutaneous Tepezza Matches Infusion in Phase 3 Trial, Amgen Reports
As reported on BioPharmaDive, Amgen has announced positive Phase 3 results for a subcutaneous version of its thyroid eye disease (TED) therapy Tepezza, suggesting the new formulation performs similarly to the original intravenous infusion. The findings may strengthen Amgen’s position as competition intensifies in a market where convenience and access remain key challenges. The study […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
